channel 7 parkinson, page-4

We're getting close to the time when investors will start thinking seriously about the outcome of the current trial because the pass/fail evaluation is very real. IIL is finished because their trial failed to show any efficacy, and the successful anecdotes on which the company had based its hopes turned out to be nothing more than a placebo response. Nearly 80c a share a few months ago, now 4c, and likely worthless.

I don't think we will see any ramping from LCT before the result, no "pump and dumps" here. But I think the reality is that if they are successful the share price maybe will double from here, and surge again when they start commercial operations, and LCT and NTcell will get significant worldwide media coverage.

Time for most investors to assess the risks of the gamble and the probability of success, maybe look back at the completed trail and try to gauge the confidence of the BOD.

Meantime it looks to me as though the buy and sell sides of the current trading are being staged managed by a sophisticated holder to maintain a price around 10.5c. A significant rise might attract attention from technical traders.